MAVERIX BIOMICS, INC.

SAN MATEO, CA · Founded 2010 · CIK 0001595711 · Biotech · Private

Sequence-based analysis platform and knowledgebase for identifying extended spectrum beta-lactamase (ESBL) resistance mutations in bacterial genomes

Grants
$370K
2 awards
Sector median: 1
Raised
$8.0M
1 Form D · Jan 2014
154 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$7,993,889
Federal grantDepartment of Health and Human Services · Phase I · A high-throughput kit for detection of RNA modifications$149,952
Federal grantDepartment of Health and Human Services · Phase I · Development of a Genotype-linked Antibiotic Resistance Platform for Real Time Pathogen Risk Classification and Epidemiology$219,655
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3344WILLIAM D SHANNON CONSULTING LLC——
3345Enara Bio——
3346FLASHPOINT THE ACADEMY OF MEDIA ARTS & SCIENCES LLC—$1.0M
3347MAVERIX BIOMICS, INC.—$8.0M
3348Attovia Therapeutics——
3349CETYA THERAPEUTICS, INC.——
3350Aethl Bio, Inc.—$1.6M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 5 related persons
  • Patricia ChanExecutive Officer
  • Todd LoweDirector · Executive Officer · Promoter
  • David MandelkernDirector · Executive Officer · Promoter
  • Paul PickeringExecutive Officer
  • Gordon RingoldDirector · Promoter

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.